Fourth, the results from colocalization analysis, PheWAS, multivariable MR, and other sensitivity MR analyses suggested that the effect of SGLT2 inhibition on prostate cancer is unlikely to violate the exchangeability and the exclusion restriction assumptions of MR. Here, SLC5A2 is linked to prostate carcinoma.